If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
== Events == 6 January - The William and Mary founders in the Irish Sea off Milford Haven, Pembrokeshire, with the loss of all hands. 9 January - The ship Cecelia, on a voyage from Dublin to Barbados, founders in the Irish Sea off Holyhead, Anglesey, with the loss of all hands. 10 March - The ship Prosperous founders off Anglesey with the loss of all hands. 6 May - The first Welsh language version of the New Testament issued by the British and Foreign Bible Society is published. 1 October - The brig Mary runs aground on the Arklow Bank, in the Irish Sea and is wrecked with the loss of seven of the ten people on board. Two of the survivors are rescued by Mary, a ship homeported in Liverpool, Lancashire, whilst the third is rescued by Mary, a ship homeported in Amlwch, Anglesey. 25 October - The sloop Margaret, on a voyage from Bristol, Gloucestershire to Greenock, Renfrewshire, is wrecked near Holyhead, Anglesey, with the loss of all on board. 3 December - Ships affected by a storm in the Irish Sea include: Eliza, driven ashore at Cardigan, Pembrokeshire, on a voyage from Virginia, United States to Dublin. Her crew are rescued. John, on a voyage from Youghal, County Cork to Dublin, driven ashore at Caernarfon. Milford, driven ashore at Cardigan while on a voyage from Liverpool to Wilmington, Delaware, United States. Her crew are rescued. The first Nonconformist school in Wales is opened at Swansea. William Madocks obtains an Act of Parliament to allow him to construct a harbour at Portinllaen. William Owen Pughe inherits the estate of the Rev.
sister chromatids A pair of identical copies (chromatids) produced as the result of the DNA replication of a chromosome, particularly when both copies are joined together by a common centromere; the pair of sister chromatids is called a dyad. The two sister chromatids are ultimately separated from each other into two different cells during mitosis or meiosis.
== Types == The structure of the nanotube is not changed if the strip is rotated by 60 degrees clockwise around A1 before applying the hypothetical reconstruction above. Such a rotation changes the corresponding pair (n,m) to the pair (−m,n+m). It follows that many possible positions of A2 relative to A1 — that is, many pairs (n,m) — correspond to the same arrangement of atoms on the nanotube. That is the case, for example, of the six pairs (1,2), (−2,3), (−3,1), (−1,−2), (2,−3), and (3,−1). In particular, the pairs (k,0) and (0,k) describe the same nanotube geometry. These redundancies can be avoided by considering only pairs (n,m) such that n > 0 and m ≥ 0; that is, where the direction of the vector w lies between those of u (inclusive) and v (exclusive). It can be verified that every nanotube has exactly one pair (n,m) that satisfies those conditions, which is called the tube's type. Conversely, for every type there is a hypothetical nanotube. In fact, two nanotubes have the same type if and only if one can be conceptually rotated and translated so as to match the other exactly. Instead of the type (n,m), the structure of a carbon nanotube can be specified by giving the length of the vector w (that is, the circumference of the nanotube), and the angle α between the directions of u and w may range from 0 (inclusive) to 60 degrees clockwise (exclusive). If the diagram is drawn with u horizontal, the latter is the tilt of the strip away from the vertical.
The agency "is also working with its regulatory partners in all 50 state agriculture and health agencies to inform them of the status of the investigative and analytical efforts." The FDA issued an alert to its field personnel that they should block import of wheat gluten from Xuzhou Anying Biologic Technology Development Company Ltd., and subject wheat gluten from China and the Netherlands to increased scrutiny. As a result of the contamination, consumers and pets' rights groups have called for the FDA to take a more active role in ensuring pet food safety. On 2 April 2007, People for the Ethical Treatment of Animals called for the resignation of the FDA's commissioner, Dr. Andrew von Eschenbach. Possibly in response to growing concern about ensuring the safety of the U.S. food supply, on 1 May 2007, Dr. von Eschenbach announced the creation of an Assistant Commissioner for Food Protection to advise on "strategic and substantive food safety and food defense matters." Dr. David Acheson will fill this roll. According to Dr. von Eschenbach, "The protection of America's food supply and therefore the safety of Americans eating food of domestic or international origin is of utmost importance to me as a physician, and to the mission of this agency."
On 26 February, after setting 737 of Kuwait's oil wells on fire, Iraqi troops began retreating. A long convoy of retreating Iraqi troops formed along the main Iraq–Kuwait highway. This convoy was bombed so extensively by coalition air forces that it came to be known as the Highway of Death. Thousands of Iraqi troops were killed. American, British, and French forces continued to pursue retreating Iraqi forces over the border and back into Iraq, eventually moving to within 240 km (150 mi) of Baghdad, before withdrawing back to Iraq's border with Kuwait and Saudi Arabia.
Sources: en.wikipedia.org
=== Technology === Building on the foundational principles of ELISA, eSimoa employs paramagnetic beads to isolate biomolecules or enzymes in a manner akin to ELISA's plate-based detection. However, eSimoa advances this concept by enabling enzymatic reaction measurements at the single-molecule level, which dramatically improves detection limits for various enzymes and biomolecules. This method allows for the precise quantification of low-abundance proteins and the activity of critical enzymes such as protein kinases and telomerases, which are often below the detection threshold of conventional ELISA.
In August 1914 Britain entered the First World War. Tolkien's relatives were shocked when he elected not to volunteer immediately for the British Army. In a 1941 letter to his son Michael, Tolkien recalled: "In those days chaps joined up, or were scorned publicly. It was a nasty cleft to be in for a young man with too much imagination and little physical courage." Instead, Tolkien, "endured the obloquy", and entered a programme by which he delayed enlistment until completing his degree. By the time he passed his finals in July 1915, Tolkien recalled that the hints were "becoming outspoken from relatives". He was commissioned as a temporary second lieutenant in the Lancashire Fusiliers on 15 July 1915. He trained with the 13th (Reserve) Battalion on Cannock Chase, Rugeley Camp near to Rugeley, Staffordshire, for eleven months. In a letter to Edith, Tolkien complained: "Gentlemen are rare among the superiors, and even human beings rare indeed." Following their wedding Lieutenant and Mrs. Tolkien took up lodgings near the training camp. On 2 June 1916, Tolkien received a telegram summoning him to Folkestone for posting to France. The Tolkiens spent the night before his departure in a room at the Plough & Harrow Hotel in Edgbaston, Birmingham. He later wrote: "Junior officers were being killed off, a dozen a minute. Parting from my wife then ... it was like a death."
== History == MusclePharm Corporation was incorporated on August 4, 2006. On February 18, 2010, the company acquired Muscle Pharm, LLC, and as a result, MusclePharm then became a wholly owned subsidiary. In 2021, MusclePharm named Sabina Rizvi its first president and CFO. In 2023, MusclePharm named Eric Hillman CEO.
Herpetic gingivostomatitis: A self-limiting viral infection which is caused by herpes simplex virus-1 (HSV-1). It usually presents in young children and is very contagious. It is characterised by the presence of small oral blisters which break down and coalesce into ulcers. Herpes labialis (cold sore): Reactivation of latent herpes simplex virus-1 triggered by sunlight, stress, and hormonal changes. It is characterised by the presence of crusting blisters on the upper lip. Chickenpox: A type of viral infection which is caused by varicella zoster virus and presents in children. Numerous itchy blisters are found on the face and body. Blisters could also be found on inner cheek and palate of the mouth. Herpes zoster/shingles: Viral infection caused by reactivation of latent varicella zoster virus and found in adults. Patients can present with acute pain before or after the onset of blisters. If viral reactivation occurs in the facial nerve, it can cause Ramsay–Hunt syndrome in which patients can develop facial paralysis, blisters around the ears and on the tongue, and loss of tongue sensation. Hand, foot, and mouth disease: A highly contagious viral infection which infects young children and is caused by coxsackie virus A16. It is characterised by presence of small blisters all over the limbs and the mouth. Measles: A highly infectious condition which is caused by measles virus. It most commonly presents in young children who have not been vaccinated. It is characterised by presence of white spots (Koplik's spots) which rupture to form ulcers on the palate.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.